Hypothesis: In patients, who have diabetes type 2, are treated with metformin, and are
admitted for HF, leads to reduced insulin requirements, as measured in units of insulin, with
no negative impact on patient safety.
This is a single center, prospective trial. Subjects will be randomized to initiate metformin
(starting dose 500mg orally once daily up to a maximum dose of 2,500mg daily) OR be placed on
insulin products for management of their type 2 diabetes mellitus.